Deutsch English Français

Contact

EP1549290

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1549290

EP1549290 - BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING METABOLIC DISORDERS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 23.07.2010 Database last updated on 02.11.2024
Most recent event Tooltip	23.07.2010	Application deemed to be withdrawn	published on 25.08.2010 [2010/34]
Applicant(s)	For all designated states Novadel Pharma Inc. 31 State Highway 12 Flemington, NJ 08822 / US
	[2005/27]
Inventor(s)	01 / DUGGER, Harry, A., III 548 Sergeantsville Road Flemington, NJ 08822 / US
	[2005/27]
Representative(s)	Lord, Hilton David Marks & Clerk LLP 90 Long Acre London WC2E 9RA / GB
	[N/P]
Former [2005/27]	Lord, Hilton David Marks & Clerk 90 Long Acre London WC2E 9RA / GB
Application number, filing date	03791858.8	27.08.2003
	[2005/27]
	WO2003US26855
Priority number, date	US20020230084	29.08.2002 Original published format: US 230084
	[2005/27]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2004019903
	Date:	11.03.2004
	Language:	EN
	[2004/11]
	Type:	A1 Application with search report
	No.:	EP1549290
	Date:	06.07.2005
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 11.03.2004 takes the place of the publication of the European patent application.
	[2005/27]
Search report(s)	International search report - published on:	EP	11.03.2004
Classification	IPC:	A61K9/00, A61K31/00	[2005/27]
	CPC:	A61K9/006 (EP,US); A61K31/00 (EP,US); A61K31/085 (EP,US); A61K31/137 (EP,US); A61K31/138 (EP,US); A61K31/197 (EP,US); (+) A61K31/27 (EP,US); A61K31/4178 (EP,US); A61K31/421 (EP,US); A61K31/433 (EP,US); A61K31/5415 (US); A61K31/7076 (EP,US); A61K38/13 (EP,US); A61K47/10 (US); A61K47/14 (US); A61K9/0056 (EP,US); A61M11/00 (US); A61M11/02 (US); A61P1/08 (EP); A61P11/06 (EP); A61P11/08 (EP); A61P19/00 (EP); A61P25/00 (EP); A61P29/00 (EP); A61P3/00 (EP); A61P3/04 (EP); A61P3/10 (EP); A61P31/00 (EP); A61P31/04 (EP); A61P31/10 (EP); A61P31/12 (EP); A61P43/00 (EP) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2005/27]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
Title	German:	BUKKALES, POLARES UND NICHTPOLARES SPRAY ODER KAPSEL MIT MITTELN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN	[2005/27]
	English:	BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING METABOLIC DISORDERS	[2005/27]
	French:	CAPSULE OU VAPORISATEUR BUCCAL, POLAIRE ET NON POLAIRE, CONTENANT DES MEDICAMENTS POUR LE TRAITEMENT DE TROUBLES METABOLIQUES	[2005/27]
Entry into regional phase	24.03.2005	National basic fee paid
	24.03.2005	Designation fee(s) paid
	24.03.2005	Examination fee paid
Examination procedure	19.03.2004	Request for preliminary examination filed International Preliminary Examining Authority: EP
	24.03.2005	Examination requested [2005/27]
	25.03.2005	Amendment by applicant (claims and/or description)
	02.03.2010	Application deemed to be withdrawn, date of legal effect [2010/34]
	08.04.2010	Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2010/34]
Fees paid	Renewal fee
	12.08.2005	Renewal fee patent year 03
	14.08.2006	Renewal fee patent year 04
	14.08.2007	Renewal fee patent year 05
	31.03.2008	Renewal fee patent year 06
	Penalty fee
	Additional fee for renewal fee
	31.08.2009	07 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]WO9916417 (FLEMINGTON PHARMACEUTICAL CORP [US], et al) [X] 29-57,83-110 * pages 6-9; examples 1-11; claims 2-23,42,43 *;
		[X]DE3338978 (BASF AG [DE]) [X] 1-28,58-82 * examples 3-5; claim 3 *;
		[X]EP0471161 (SANOL ARZNEI SCHWARZ GMBH [DE]) [X] 1-28 * column 3; examples 1-3; claims 1-15 *;
		[X]DE3246081 (POHL BOSKAMP GMBH CHEM PHARMA [DE]) [X] 83-111 * examples 1,2; claims 1,2 *;
		[X]US5428006 (BECHGAARD ERIK [DK], et al) [X] 1-28,58-82 * column 3 - column 7; examples 1-13; claims 1-22 *;
		[X]WO9304671 (MINNESOTA MINING & MFG [US]) [X] 83-111 * examples 1-11; claims 1-17 *;
		[X]US5869082 (DUGGER III HARRY A [US]) [X] 83-111 * examples 1-4; claims 1-16 *;
		[X]EP0656206 (SCHERING CORP [US]) [X] 83-111 * page 6 - page 12; claims 1-12 *;
		[X]US5955098 (DUGGER III HARRY A [US]) [X] 83-111 * examples 1-5; claims 1-18 *;
		[X]US5635161 (ADJEI AKWETE L [US], et al) [X] 29-57,83-111 * examples 1-5; claims 1-15 *;
		[X]US6299900 (REED BARRY LEONARD [AU], et al) [X] 29-57 * examples 14,15; claims 10,20-24 *;
		[X]WO9738662 (FLEMINGTON PHARMACEUTICAL CORP [US], et al) [X] 1-28 * claims 1-13 *;
		[X]WO9413280 (MAYOR PHARMA LAB INC [US], et al) [X] 1-28 * example 1; claims 1-6 *;
		[X]US5502076 (DIXIT SURESH C [US], et al) [X] 29-57,83-111 * examples 1-6; claims 1-14 *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p